Lanean...
Ivacaftor: A Novel Gene-Based Therapeutic Approach for Cystic Fibrosis
Ivacaftor is a new therapeutic agent that acts at the cystic fibrosis transmembrane conductance regulator (CFTR) channel to alter activity. It is approved for use in patients 6 years and older with cystic fibrosis who have at least 1 G551D mutation in the CFTR gene. It is unlike any other current ph...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Pediatric Pharmacy Advocacy Group
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3626070/ https://ncbi.nlm.nih.gov/pubmed/23616732 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5863/1551-6776-18.1.8 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|